Kiniksa Pharmaceuticals Ltd (KNSA) FinancialsKNSAKiniksa Pharmaceuticals Ltd

Evaluating the bottom line, Kiniksa Pharmaceuticals International, PLC maintains a gross margin of 90.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.16%, while the net margin is 10.44%. These profitability ratios, combined with a Return on Equity (ROE) of 14.04%, provide a clear picture of how effectively KNSA converts its operational activities into shareholder value.

In the context of the broader market, KNSA competes directly with industry leaders such as AMRX and GRFS. With a market capitalization of $6.13B, it holds a leading position in the sector. When comparing efficiency, KNSA's gross margin of 90.32% stands against AMRX's 42.01% and GRFS's 37.57%. Such benchmarking helps identify whether Kiniksa Pharmaceuticals International, PLC is trading at a premium or discount relative to its financial performance.

Kiniksa has shown strong financial performance with a gross margin of 90.32% and a net income of $25.4 million in Q2 2026, reflecting a 43% increase year-over-year. The company has also raised its full-year revenue guidance to $980 million to $995 million, indicating confidence in continued growth.